2023 Women in Bio­phar­ma R&D; Biotech hope­ful for re­bound even as new wave of lay­offs hit; No­var­tis' siR­NA buy­out; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

The breadth and depth of End­points re­port­ing were on full dis­play this week. There’s our an­nu­al Women in Bio­phar­ma R&D re­port, fea­tur­ing a col­lec­tion of re­al­ly in­ter­est­ing pro­files; and our re­porters al­so brought us scoops and ex­clu­sive in­ter­views on com­pa­ny fi­nanc­ings, deep analy­sis on key da­ta, an in­side look in­to com­pa­ny dy­nam­ics at Grail, and more. If you find this re­cap help­ful, we would ap­pre­ci­ate you spread­ing the word.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER